Kalir A, Sabbagh A, Youdim M B
Br J Pharmacol. 1981 May;73(1):55-64. doi: 10.1111/j.1476-5381.1981.tb16771.x.
1 A number of aromatic-N-propargyl (acetylenic) compounds and indoleamines were tested for their inhibitory action on monoamine oxidase (MAO) type A and type B using the substrates 5-hydroxytryptamine (5-HT), beta-phenylethylamine (PEA) and dopamine. 2 Structure activity studies with aromatic-N-propragyl (acetylenic) derivatives have shown that MAO inhibitory potency is least dependent on the aromatic portion of the compounds. N-methylated propargyl derivatives are the most active and replacement of the methyl group with a higher alkyl or aromatic group results in significant reduction of activity. The triple bond in the N-propargyl portion is absolutely essential for activity and must be beta-to the nitrogen. It is the acetylenic group that gives these compounds their irreversible MAO inhibitory property. 3 The present study has indicated that since the acetylenic compounds resemble the enzyme substrates the distance between the aromatic ring and the N-propargyl terminal is crucial in designating the type A or type B MAO inhibitory property. For MAO type A inhibition, a distance equivalent to at least three carbon units is required, while for the inhibition of the B type enzyme this distance can be 1 or 2 carbon units. 4 The compounds AGN-1133 and AGN-1135 show most promise in Parkinson's disease or as anti-depressants because of their irreversible selective type B MAO inhibition in vitro and in vivo. 5 A number of indoleamine derivatives were found to be reversible selective type A inhibitors.
使用底物5-羟色胺(5-HT)、β-苯乙胺(PEA)和多巴胺,对多种芳香族-N-炔丙基(乙炔基)化合物和吲哚胺进行了它们对A型和B型单胺氧化酶(MAO)抑制作用的测试。
对芳香族-N-炔丙基(乙炔基)衍生物的构效关系研究表明,MAO抑制效力对化合物的芳香部分依赖性最小。N-甲基化炔丙基衍生物活性最高,用更高的烷基或芳香基取代甲基会导致活性显著降低。N-炔丙基部分的三键对活性绝对至关重要,且必须位于氮的β位。正是乙炔基赋予了这些化合物不可逆的MAO抑制特性。
本研究表明,由于乙炔基化合物类似于酶底物,芳香环与N-炔丙基末端之间的距离在确定A型或B型MAO抑制特性方面至关重要。对于A型MAO抑制,需要至少相当于三个碳单元的距离,而对于B型酶的抑制,这个距离可以是1或2个碳单元。
化合物AGN-1133和AGN-1s35在帕金森病或作为抗抑郁药方面显示出最大的潜力,因为它们在体外和体内具有不可逆的选择性B型MAO抑制作用。
发现多种吲哚胺衍生物是可逆的选择性A型抑制剂。